SLC2A1 and type 2 diabetes mellitus: These studies with type 2 diabetes mellitus (T2DM) mice model suggested that SIRT6 inhibitors increased oral glucose tolerance by upregulating the expression of GLUT1 and GLUT4 in muscle and enhancing glycolytic activity.